[Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
OBJECTIVE
A previous large randomized control study(IALT)revealed that cisplatin(CDDP)-based adjuvant chemotherapy was not effective for patients with ERCC1-positive non-small cell lung cancer(NSCLC). We evaluated the chemosensitivity of surgically resected specimens of NSCLC using in vitro chemosensitivity test and searched for promising adjuvant chemotherapy protocols in the ERCC1-positive subgroup of NSCLC.


METHODS
Chemosensitivities of 10 anticancer agents including cisplatin were evaluated by histoculture drug response assay(HDRA) using 28 surgically resected NSCLC specimens. ERCC 1 status was evaluated by immunohistochemistry.


RESULTS
ERCC1 was positive in 22 and negative in 6 specimens. All ERCC1-negative specimens were sensitive for CDDP in HDRA, and all CDDP-resistant specimens in HDRA showed positive ERCC1 staining. ERCC1 status was significantly correlated with CDDP sensitivity(p=0.01). HDRA showed average 3(0-6)sensitive anticancer agents except for CDDP even in ERCC1-positive specimens.


CONCLUSIONS
HDRA may provide effective non-platinum adjuvant chemotherapy protocols for patients with ERCC1-positive, i.e. CDDP resistant, NSCLC.
Hirai
Yoshimitsu
Y
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University.
Yoshimasu
Tatsuya
T
Oura
Shoji
S
Tamaki
Takeshi
T
Ota
Fuminori
F
Nakamura
Rie
R
Shimizu
Yukio
Y
Naito
Koma
K
Ota
Megumi
M
Miyasaka
Miwako
M
Okamura
Yoshitaka
Y
Nakamura
Yasushi
Y
Yasuoka
Hironao
H
Kodama
Rieko
R
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001681:Biological Assay / Q000379:methods*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004720:Endonucleases / Q000032:analysis* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D046509:Tissue Culture Techniques
D000970:Antineoplastic Agents; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases